Literature DB >> 10665556

Results at 1 year of outpatient multidisciplinary pulmonary rehabilitation: a randomised controlled trial.

T L Griffiths1, M L Burr, I A Campbell, V Lewis-Jenkins, J Mullins, K Shiels, P J Turner-Lawlor, N Payne, R G Newcombe, A A Ionescu, J Thomas, J Tunbridge, A A Lonescu.   

Abstract

BACKGROUND: Pulmonary rehabilitation seems to be an effective intervention in patients with chronic obstructive pulmonary disease. We undertook a randomised controlled trial to assess the effect of outpatient pulmonary rehabilitation on use of health care and patients' wellbeing over 1 year.
METHODS: 200 patients with disabling chronic lung disease (the majority with chronic obstructive pulmonary disease) were randomly assigned a 6-week multidisciplinary rehabilitation programme (18 visits) or standard medical management. Use of health services was assessed from hospital and general-practice records. Analysis was by intention to treat.
FINDINGS: There was no difference between the rehabilitation (n=99) and control (n=101) groups in the number of patients admitted to hospital (40 vs 41) but the number of days these patients spent in hospital differed significantly (mean 10.4 [SD 9.7] vs 21.0 [20.7], p=0.022). The rehabilitation group had more primary-care consultations at the general-practitioner's premises than did the control group (8.6 [6.8] vs 7.3 [8.3], p=0.033) but fewer primary-care home visits (1.5 [2.8] vs 2.8 [4.6], p=0.037). Compared with control, the rehabilitation group also showed greater improvements in walking ability and in general and disease-specific health status.
INTERPRETATION: For patients chronically disabled by obstructive pulmonary disease, an intensive, multidisciplinary, outpatient programme of rehabilitation is an effective intervention, in the short term and the long term, that decreases use of health services.

Entities:  

Mesh:

Year:  2000        PMID: 10665556     DOI: 10.1016/s0140-6736(99)07042-7

Source DB:  PubMed          Journal:  Lancet        ISSN: 0140-6736            Impact factor:   79.321


  165 in total

Review 1.  Enhancing physical performance in chronic obstructive pulmonary disease.

Authors:  M C Steiner; M D Morgan
Journal:  Thorax       Date:  2001-01       Impact factor: 9.139

Review 2.  Effective physiotherapy.

Authors:  R D Herbert; C G Maher; A M Moseley; C Sherrington
Journal:  BMJ       Date:  2001-10-06

Review 3.  Oral mucolytic drugs for exacerbations of chronic obstructive pulmonary disease: systematic review.

Authors:  P J Poole; P N Black
Journal:  BMJ       Date:  2001-05-26

Review 4.  Pulmonary rehabilitation.

Authors: 
Journal:  Thorax       Date:  2001-11       Impact factor: 9.139

5.  Health status measurement: sensitivity of the self-reported Chronic Respiratory Questionnaire (CRQ-SR) in pulmonary rehabilitation.

Authors:  J E A Williams; S J Singh; L Sewell; M D L Morgan
Journal:  Thorax       Date:  2003-06       Impact factor: 9.139

Review 6.  Management of an acute exacerbation of copd: are we ignoring the evidence?

Authors:  M K Johnson; R D Stevenson
Journal:  Thorax       Date:  2002-10       Impact factor: 9.139

7.  Long-term effects of a maintenance program after supervised or self-monitored training programs in patients with COPD.

Authors:  L Puente-Maestu; M Luisa Sánz; P Sánz; Ruíz J M de Oña; A Arnedillo; R Casaburi
Journal:  Lung       Date:  2003       Impact factor: 2.584

8.  The new contract: renaissance or requiem for general practice?

Authors:  Martin Marshall; Martin Roland
Journal:  Br J Gen Pract       Date:  2002-07       Impact factor: 5.386

9.  Rehabilitation for patients with chronic obstructive pulmonary disease: meta-analysis of randomized controlled trials.

Authors:  Ghassan F Salman; Michael C Mosier; Brent W Beasley; David R Calkins
Journal:  J Gen Intern Med       Date:  2003-03       Impact factor: 5.128

10.  A pilot study of pulmonary rehabilitation in primary care.

Authors:  Rupert C M Jones; Shirley Copper; Oksana Riley; Frank Dobbs
Journal:  Br J Gen Pract       Date:  2002-07       Impact factor: 5.386

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.